ArticleIndian journal of pharmacology2025
Efficacy of epigallocatechin-3-gallate against oleic acid-induced acute respiratory distress syndrome.
Article in Indian journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective is to induce acute respiratory distress syndrome (ARDS) in rats by oleic acid and evaluate the prophylactic and therapeutic effectiveness of epigallocatechin-3-gallate (EGCG) against ARDS.
backgroundARDS is an acute, severe inflammatory lung injury. Clinically used anti-inflammatory medication and corticosteroids have side effects, infection risk, and increased treatment costs. Epigallocatechin-3-gallate (EGCG) from green tea is a flavonoid possessing antioxidant and anti-inflammatory properties. Intravenous injection of pure oleic acid causes respiratory distress in diverse animal species, leading to inflammation in the lungs. Hence, we used oleic acid to induce ARDS in rats to assess the prophylactic and therapeutic effectiveness of EGCG against ARDS. MATERIALS AND
methodsA total of four groups were formed, with five animals allocated to each group. The control group (G1) was administered with normal saline 0.2 ml/kg, twice at an interval of 1 h, ARDS group (G2) with oleic acid 0.2 ml/kg intravenously, twice at 1-h interval. The prophylactic group (G3) was administered with EGCG 10 mg/kg i.p. 1 h before the administration of oleic acid, whereas therapeutic group (G4) was administered with same dose of EGCG but, 1 h after the administration of oleic acid.
resultsAssessment of animal body and lungs weight, gross macroscopic and microscopic evaluation of lungs did not produce any significant treatment-related changes when compared with the control group. However, a substantial decrease in tumor necrosis factor-alpha levels was observed in G3 and G4 when compared to the G2 group.
conclusionsEGCG has both prophylactic and therapeutic effectiveness against ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.